Michael J. Zelefsky, MD, presented “The Importance of a Post-Treatment Biopsy in the Management of Patients Treated with Radiotherapy for Localized Prostate Cancer” during the 24th Annual Southwest Prostate Cancer Symposium on April 12, 2019 in Scottsdale, Arizona.
How to cite: Zelefsky, Michael J.. “Combining SBRT and Brachytherapy in Higher Risk Prostate Cancer” April 12, 2019. Accessed Apr 2024. https://dev.grandroundsinurology.com/the-importance-of-a-post-treatment-biopsy-in-the-management-of-patients-treated-with-radiotherapy-for-localized-prostate-cancer/
The Importance of a Post-Treatment Biopsy in the Management of Patients Treated with Radiotherapy for Localized Prostate Cancer – Summary:
Michael J. Zelefsky, MD, discusses the use of post-radiotherapy prostate biopsy to assess local tumor control following radiotherapy. He argues that post-treatment biopsy can benefit patients by allowing for earlier identification of local recurrences and initiation of salvage therapy than would be possible when relying upon PSA and multiparametric MRI.
About the Southwest Prostate Cancer Symposium
The Southwest Prostate Cancer Symposium (SPCS) is a multi-day conference that seeks to educate urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. The topics focus on current technical aspects of diagnosis and treatment of localized and advanced disease, particularly regarding imaging, technology, and training in the related devices. Dr. Zelefsky presented this lecture during the 24th SPCS in 2019. In 2020, the 25th SPCS will also offer training sessions involving imaging, scanning, and prostate cancer treatment-related devices on site. Please visit this page in order to register for future SPCS meetings.
